Skip to content

Current Neuropharmacology

ISSN 1570-159X, 1875-6190

45 papers in the library · 1,702 citations · publishing 2011-2026

Papers

Sort Most recent Most cited

The e-Psychonauts' 'Spiced' World; Assessment of the Synthetic Cannabinoids' Information Available Online.

Current Neuropharmacology 2020 Caroline Zangani, Fabrizio Schifano, Flavia Napoletano et al.

Background: A wide range of novel psychoactive substances (NPS) is regularly searched and discussed online by web-based drug enthusiasts (i.e. the e-psychonauts). Among NPS, the range of synthetic cannabinoids (SC; 'Spice') currently represents a challenge for governments and clinicians. Methods: Using a web crawler (i.e. the NPS.Finder®), the present study aimed at assessing psychonauts'...

Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness

Current Neuropharmacology March 2, 2018 Jonathan Hamill, Jaime E. C. Hallak, Serdar Dursun et al. 179 citations

Background: Ayahuasca, a traditional Amazonian decoction with psychoactive properties, is made from bark of the Banisteriopsis caapi vine (containing beta-carboline alkaloids) and leaves of the Psychotria viridis bush (supplying the hallucinogen N,N-dimethyltryptamine, DMT). Originally used by indigenous shamans for the purposes of spirit communication, magical experiences, healing, and...

Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications

Current Neuropharmacology June 19, 2017 Rainer Kraehenmann 90 citations

The broad overlap between dreaming and psychedelic states supports the notion that psychedelics acutely induce dreamlike subjective experiences which may have long-term beneficial effects on psychosocial functioning and well-being. Future clinical studies should examine how therapeutic outcome is related to the acute dreamlike effects of psychedelics.

Beyond Ketamine: New Approaches to the Development of Safer Antidepressants

Current Neuropharmacology February 23, 2017 Shigeyuki Chaki 40 citations

BACKGROUND: Ketamine has been reported to exert rapid and sustained antidepressant effects in patients with depression, including patients with treatment-resistant depression. However, ketamine has several drawbacks such as psychotomimetic/dissociative symptoms, abuse potential and neurotoxicity, all of which prevent its routine use in daily clinical practice. METHODS: Therefore, development of...

Evolutionary Considerations on the Emerging Subculture of the E-psychonauts and the Novel Psychoactive Substances: A Comeback to the Shamanism?

Current Neuropharmacology December 2, 2016 Laura Orsolini, Paul St John‐smith, Daniel Mcqueen et al. 28 citations

Indeed, a range of evolutionary mechanisms, such as: optimal foraging, costly signaling, and reproduction at the expense of health may all cooperate to explain the recent spread and diffusion of the NPS market, and this may represent a reason of concern.

DOI: 10.2174/1570159x15666161111114838 (opens in new tab) Shamanism Psychoactive substance Mechanism biology Subculture biology +1

Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder

Current Neuropharmacology March 25, 2016 Brittany A. Jaso, Mark J. Niciu, Nicolas D. Iadarola et al. 97 citations

Current pharmacotherapies for major depressive disorder (MDD) have a distinct lag of onset that can prolong distress and impairment for patients, and realworld effectiveness trials further suggest that antidepressant efficacy is limited in many patients. All currently approved antidepressant medications for MDD act primarily through monoaminergic mechanisms, e.g., receptor/reuptake agonists or...

DOI: 10.2174/1570159x14666160321123221 (opens in new tab) Full text (opens in new tab) Nmda receptor Antidepressant Pharmacology Metabotropic glutamate receptor +3

Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine

Current Neuropharmacology March 10, 2016 Eric S. Wohleb, Danielle M. Gerhard, Alex Thomas et al. 148 citations

Major depressive disorder (MDD) is a prevalent neuropsychiatric disease that causes profound social and economic burdens. The impact of MDD is compounded by the limited therapeutic efficacy and delay of weeks to months of currently available medications. These issues highlight the need for more efficacious and faster-acting treatments to alleviate the burdens of MDD. Recent breakthroughs...

Kappa Opioids, Salvinorin A and Major Depressive Disorder.

Current Neuropharmacology 2016 George T Taylor, Francesca Manzella

Opioids are traditionally associated with pain, analgesia and drug abuse. It is now clear, however, that the opioids are central players in mood. The implications for mood disorders, particularly clinical depression, suggest a paradigm shift from the monoamine neurotransmitters to the opioids either alone or in interaction with monoamine neurons. We have a special interest in dynorphin, the...

Recreational Use, Analysis and Toxicity of Tryptamines

Current Neuropharmacology December 10, 2014 Roberta Tittarelli, Giulio Mannocchi, Flaminia Pantano et al. 217 citations

Information from Internet and from published scientific literature, organized in the way we proposed in this review, provides an effective tool for specialists facing the emerging NPS threat to public health and public security, including the personnel working in Emergency Department.

The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review

Current Neuropharmacology November 12, 2014 Gianluca Serafini, Robert H Howland, Fabiana Rovedi et al. 238 citations

BACKGROUND: At least 10-20% of the patients suffering from depression meet criteria for treatment-resistant depression (TRD). In the last decades, an important role of glutamate in mood modulation has been hypothesized and ketamine, a non noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptors, has been demonstrated to be effective in both MDD and TRD. However, concerns emerged...

MDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen Pharmacology

Current Neuropharmacology August 1, 2013 Patricio Sáez-briones, Alejandro Hernández 41 citations

Besides stimulants and hallucinogens, whose psychotropic effects are shared by many structurally related molecules exhibiting different efficacies and potencies in humans, the phenylisopropylamine MDMA (3,4-methylenedioxymethamphetamine, XTC, "Ecstasy") is the prototypical representative of a separate class of psychotropic substance, able to elicit the so-called entactogenic syndrome in healthy...

Ketamine as Antidepressant? Current State and Future Perspectives

Current Neuropharmacology August 1, 2013 Helge Hasselmann 36 citations

Major depressive disorder (MDD) is a serious mental disorder that ranks among the major causes of disease burden. Standard medical treatment targeting cerebral monoamines often provides only insufficient symptom relief and fails in approximately every fifth patient. The complexity of MDD therefore, reflects more than monoaminergic dysregulation. Initial research argues the case for excessive...

Effects of MDMA on Extracellular Dopamine and Serotonin Levels in Mice Lacking Dopamine and/or Serotonin Transporters

Current Neuropharmacology March 1, 2011 Yoko Hagino, Yukio Takamatsu, Hideko Yamamoto et al. 64 citations

3,4-Methylendioxymethamphetamine (MDMA) has both stimulatory and hallucinogenic properties which make its psychoactive effects unique and different from those of typical psychostimulant and hallucinogenic agents. The present study investigated the effects of MDMA on extracellular dopamine (DA(ex)) and serotonin (5-HT(ex)) levels in the striatum and prefrontal cortex (PFC) using in vivo...

DOI: 10.2174/157015911795017254 (opens in new tab) MDMA Serotonin transporter Dopamine transporter Pharmacology +2

The Nature of 3, 4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonergic Dysfunction: Evidence for and Against the Neurodegeneration Hypothesis

Current Neuropharmacology March 1, 2011 Dominik K. Biezonski, Jerrold S. Meyer 51 citations

High doses of the recreational drug 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") have been well-documented to reduce the expression of serotonergic markers in several forebrain regions of rats and nonhuman primates. Neuroimaging studies further suggest that at least one of these markers, the plasma membrane serotonin transporter (SERT), may also be reduced in heavy Ecstasy users. Such...

Methylone and Monoamine Transporters: Correlation with Toxicity

Current Neuropharmacology March 1, 2011 Chiharu Sogawa, Norio Sogawa, Kazumi Ohyama et al. 50 citations

Methylone (2-methylamino-1-[3,4-methylenedioxyphenyl]propane-1-one) is a synthetic hallucinogenic amphetamine analog, like MDMA (3,4-methylenedioxy- methamphetamine), considered to act on monoaminergic systems. However, the psychopharmacological profile of its cytotoxicity as a consequence of monoaminergic deficits remains unclear. We examined here the effects of methylone on the transporters...

Analysis of electrical brain waves in neurotoxicology: γ-hydroxybutyrate.

Current Neuropharmacology March 1, 2011 Zbigniew Binienda, Michael A Beaudoin, Brett T Thorn et al. 10 citations

Advances in computer technology have allowed quantification of the electroencephalogram (EEG) and expansion of quantitative EEG (qEEG) analysis in neurophysiology, as well as clinical neurology, with great success. Among the variety of techniques in this field, frequency (spectral) analysis using Fast Fourier Transforms (FFT) provides a sensitive tool for time-course studies of different...

Impaired Spatial Memory after Ketamine Administration in Chronic Low Doses

Current Neuropharmacology March 1, 2011 Carlos Venâncio, Ana Magalhães, Luís Antunes et al.

Ketamine is a noncompetitive antagonist of the NMDA-receptors, used as a dissociative anesthetic, presently included in the category of the psychoactive substances known as “club drugs”. Ketamine administration was associated with impaired working memory and increased psychopathological symptoms, but there is a lack of information regarding the effects of chronic sub-anesthetic doses. Adult...

Inhibition of g protein-activated inwardly rectifying k channels by phencyclidine.

Current Neuropharmacology March 2011 Toru Kobayashi, Daisuke Nishizawa, Kazutaka Ikeda

Addictive drugs, such as opioids, ethanol, cocaine, amphetamine, and phencyclidine (PCP), affect many functions of the nervous system and peripheral organs, resulting in severe health problems. G protein-activated inwardly rectifying K(+) (GIRK, Kir3) channels play an important role in regulating neuronal excitability through activation of various Gi/o protein-coupled receptors including opioid...

DOI: 10.2174/157015911795017407 (opens in new tab) Full text (opens in new tab) Girk channel Kir channel Phencyclidine Xenopus oocyte. +1

Ketamine-induced neurotoxicity and changes in gene expression in the developing rat brain.

Current Neuropharmacology March 2011 Fang Liu, Merle G. Paule, Syed F. Ali et al.

Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is widely used for analgesia and anesthesia in obstetric and pediatric practice. Recent reports indicate that ketamine causes neuronal cell death in developing rodents and nonhuman primates. The present study assessed the potential dose- and time-dependent neurotoxic effects and associated changes in gene expression after ketamine...

DOI: 10.2174/157015911795017155 (opens in new tab) Full text (opens in new tab) Ketamine N-methyl-d-aspartate nmda receptor Apoptosis In situ hybridization +1